Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

GoodRx shares soar after announcing the company's partnership with Novo Nordisk to slash the cost of Ozempic. GoodRx CEO ...

The transaction is led by MCR Investors and its Chairman and CEO, Tyler Morse, with financing from Apollo and Goldman Sachs ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18 after Bagsværd-headquartered Novo Nordisk (NYSE: ...

GoodRx is collaborating with Novo Nordisk to offer its weight-loss drugs to self-paying patients at lower costs. The prescription-drug provider said Monday that all strengths of Ozempic and Wegovy ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don't go through ...